JP2020503265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503265A5 JP2020503265A5 JP2019527321A JP2019527321A JP2020503265A5 JP 2020503265 A5 JP2020503265 A5 JP 2020503265A5 JP 2019527321 A JP2019527321 A JP 2019527321A JP 2019527321 A JP2019527321 A JP 2019527321A JP 2020503265 A5 JP2020503265 A5 JP 2020503265A5
- Authority
- JP
- Japan
- Prior art keywords
- raav
- vector according
- pharmaceutical composition
- virus
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022112657A JP2022137210A (ja) | 2016-11-17 | 2022-07-13 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| JP2024008380A JP7862454B2 (ja) | 2016-11-17 | 2024-01-24 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423618P | 2016-11-17 | 2016-11-17 | |
| US62/423,618 | 2016-11-17 | ||
| PCT/US2017/062371 WO2018094251A1 (en) | 2016-11-17 | 2017-11-17 | Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112657A Division JP2022137210A (ja) | 2016-11-17 | 2022-07-13 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503265A JP2020503265A (ja) | 2020-01-30 |
| JP2020503265A5 true JP2020503265A5 (enExample) | 2022-04-13 |
| JP7106534B2 JP7106534B2 (ja) | 2022-07-26 |
Family
ID=62145776
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527321A Active JP7106534B2 (ja) | 2016-11-17 | 2017-11-17 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| JP2022112657A Pending JP2022137210A (ja) | 2016-11-17 | 2022-07-13 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112657A Pending JP2022137210A (ja) | 2016-11-17 | 2022-07-13 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11583564B2 (enExample) |
| EP (1) | EP3541429A4 (enExample) |
| JP (2) | JP7106534B2 (enExample) |
| KR (1) | KR102641846B1 (enExample) |
| CN (2) | CN118490845A (enExample) |
| AU (3) | AU2017362491B2 (enExample) |
| BR (1) | BR112019009834B1 (enExample) |
| CA (1) | CA3044291A1 (enExample) |
| CL (1) | CL2019001354A1 (enExample) |
| IL (2) | IL266678B2 (enExample) |
| MA (1) | MA46863A (enExample) |
| MX (1) | MX2019005874A (enExample) |
| SA (1) | SA519401806B1 (enExample) |
| SG (1) | SG10202105090WA (enExample) |
| WO (1) | WO2018094251A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018094251A1 (en) * | 2016-11-17 | 2018-05-24 | Kaspar Brian K | Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2 |
| CN120505370A (zh) | 2017-11-08 | 2025-08-19 | 诺华股份有限公司 | 制备病毒载体的手段和方法及其用途 |
| US12228571B2 (en) | 2018-06-08 | 2025-02-18 | Novartis Ag | Cell-based assay for measuring drug product potency |
| JP7691367B2 (ja) * | 2019-02-04 | 2025-06-11 | リサーチ・インスティチュート・アット・ネーションワイド・チルドレンズ・ホスピタル | Ｃｌｎ３ポリヌクレオチドのアデノ随伴ウイルス送達 |
| WO2021077101A1 (en) * | 2019-10-18 | 2021-04-22 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of disorders associated mutations in the irf2bpl gene |
| US20230211018A1 (en) * | 2019-11-22 | 2023-07-06 | Research Institute At Nationwide Children's Hospital | Materials and methods for treatment of disorders associated with the ighmbp2 gene |
| CA3216711A1 (en) | 2021-04-13 | 2022-10-20 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery |
| WO2024235164A1 (zh) * | 2023-05-15 | 2024-11-21 | 上海金珂博生物技术有限公司 | 一种Rett综合症的基因治疗 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| PT733103E (pt) | 1993-11-09 | 2004-07-30 | Targeted Genetics Corp | Criacao de elevados titulos de vectores de aav recombinantes |
| ATE272123T1 (de) | 1993-11-09 | 2004-08-15 | Ohio Med College | Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| RU2273645C9 (ru) | 1994-08-17 | 2006-11-27 | Дзе Рокефеллер Юниверсити | Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| CA2207927A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| AU722196B2 (en) | 1995-08-30 | 2000-07-27 | Genzyme Corporation | Chromatographic purification of adenovirus and AAV |
| EP1983057A3 (en) | 1995-09-08 | 2009-01-07 | Genzyme Corporation | Improved AAV vectors for gene therapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| AU723497C (en) | 1996-09-06 | 2001-10-11 | Trustees Of The University Of Pennsylvania, The | Method for recombinant adeno-associated virus-directed gene therapy |
| DK1944362T3 (en) | 1997-09-05 | 2016-01-25 | Genzyme Corp | Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| GB9916702D0 (en) | 1999-07-16 | 1999-09-15 | Cantab Pharma Res | Virus vectors and preparations and their use |
| AU2001255575B2 (en) | 2000-04-28 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| ES2526341T3 (es) | 2001-12-17 | 2015-01-09 | The Trustees Of The University Of Pennsylvania | Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| JP5830213B2 (ja) * | 2004-02-17 | 2015-12-09 | ザ ホスピタル フォー シック チルドレン | Ｍｅｃｐ２ｅ１遺伝子 |
| DK2066791T3 (da) * | 2006-10-03 | 2012-10-15 | Genzyme Corp | Genterapi for amyotrofisk lateralsklerose og andre rygmarvssygdomme |
| BRPI0906490A2 (pt) | 2008-01-15 | 2015-07-14 | Abbott Lab | Vetores de expressão de mamífero melhorados e uso dos mesmos |
| US20090246768A1 (en) * | 2008-02-15 | 2009-10-01 | Sawalha Amr H | Predicting and Diagnosing Patients With Autoimmune Disease |
| US11219696B2 (en) | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
| US9415121B2 (en) * | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| WO2015141521A1 (ja) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及び記録媒体 |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
| US10876134B2 (en) | 2014-12-16 | 2020-12-29 | Board Of Regents Of The University Of Nebraska | Gene therapy for juvenile batten disease |
| WO2018094251A1 (en) * | 2016-11-17 | 2018-05-24 | Kaspar Brian K | Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2 |
| WO2018226785A1 (en) * | 2017-06-06 | 2018-12-13 | University Of Massachusetts | Self-regulating aav vectors for safe expression of mecp2 in rett syndrome |
-
2017
- 2017-11-17 WO PCT/US2017/062371 patent/WO2018094251A1/en not_active Ceased
- 2017-11-17 MX MX2019005874A patent/MX2019005874A/es unknown
- 2017-11-17 MA MA046863A patent/MA46863A/fr unknown
- 2017-11-17 EP EP17872045.4A patent/EP3541429A4/en active Pending
- 2017-11-17 KR KR1020197017104A patent/KR102641846B1/ko active Active
- 2017-11-17 BR BR112019009834-8A patent/BR112019009834B1/pt active IP Right Grant
- 2017-11-17 IL IL266678A patent/IL266678B2/en unknown
- 2017-11-17 SG SG10202105090WA patent/SG10202105090WA/en unknown
- 2017-11-17 US US16/461,837 patent/US11583564B2/en active Active
- 2017-11-17 CN CN202410270436.6A patent/CN118490845A/zh active Pending
- 2017-11-17 JP JP2019527321A patent/JP7106534B2/ja active Active
- 2017-11-17 CA CA3044291A patent/CA3044291A1/en active Pending
- 2017-11-17 IL IL322146A patent/IL322146A/en unknown
- 2017-11-17 CN CN201780072105.XA patent/CN110325219B/zh active Active
- 2017-11-17 AU AU2017362491A patent/AU2017362491B2/en active Active
-
2019
- 2019-05-17 CL CL2019001354A patent/CL2019001354A1/es unknown
- 2019-05-17 SA SA519401806A patent/SA519401806B1/ar unknown
-
2022
- 2022-07-13 JP JP2022112657A patent/JP2022137210A/ja active Pending
-
2023
- 2023-01-02 US US18/149,151 patent/US12357663B2/en active Active
- 2023-04-28 AU AU2023202598A patent/AU2023202598B2/en active Active
-
2025
- 2025-06-20 US US19/244,103 patent/US20250312400A1/en active Pending
-
2026
- 2026-01-13 AU AU2026200191A patent/AU2026200191A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7607007B2 (ja) | 変異ａａｖ、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法 | |
| JP7818558B2 (ja) | 修飾された第ｉｘ因子、並びに、細胞、器官及び組織への遺伝子導入のための組成物、方法及び使用 | |
| JP2021510528A (ja) | 遺伝子治療のための修飾ｒＡＡＶキャプシドタンパク質 | |
| JP2020514286A5 (enExample) | ||
| JP2017531652A (ja) | Ａａｖに基づく遺伝子治療 | |
| JP7106534B2 (ja) | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 | |
| TW201629225A (zh) | 第九因子基因療法 | |
| WO2014016580A1 (en) | Transgene expression | |
| JP2025069161A (ja) | ９番染色体オープンリーディングフレーム７２遺伝子発現のモジュレーターおよびその使用 | |
| IL262459B2 (en) | Compositions and methods for increased gene expression of pklr for the treatment of pyruvate kinase deficiency | |
| JP2022500353A (ja) | Ｉｇｆ−１−暗号化ｄｎａ作製物及びｈｇｆ−暗号化ｄｎａ作製物を用いた神経病症治療 | |
| JP2023534293A5 (enExample) | ||
| CN119255814A (zh) | 脑中bag3和蛋白质的质量控制 | |
| US20200079824A1 (en) | Gene therapy for tuberous sclerosis | |
| JP2022530359A5 (enExample) | ||
| US20240335506A1 (en) | Aqp1 gene therapy to prevent radiation induced salivary hypofunction | |
| JP2020524132A5 (enExample) | ||
| JP7860176B2 (ja) | 変異ａａｖ、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法 | |
| CA3146364A1 (en) | One-step gene therapy for duchenne muscular dystrophy via gene replacement and anti-inflammation | |
| JP2025526697A (ja) | 組換えウイルスベクターに関連する有害作用の予防または緩和 | |
| JP2024505257A (ja) | 神経セロイドリポフスチン症の遺伝子治療 | |
| HK40104471A (zh) | 用於目的基因的表达盒及其应用 | |
| RU2023103235A (ru) | Модифицированный фактор ix, а также композиции, способы и варианты применения переноса генов в клетки, органы и ткани | |
| NZ748736A (en) | Treatment of complement-mediated disorders | |
| NZ724165B2 (en) | Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency |